Ftse Mib
33.707,21
-0,38%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
62.137,57
0,55%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vaxcyte Inc (PCVX) Vaxcyte Inc (PCVX) Notizie

PCVX

Vaxcyte (PCVX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCVX
DataOraFonteTitoloSimboloCompagnia
10/06/202422:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCVXVaxcyte Inc
10/06/202422:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
03/06/202422:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCVXVaxcyte Inc
24/05/202423:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PCVXVaxcyte Inc
08/05/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCVXVaxcyte Inc
08/05/202422:05GlobeNewswire Inc.Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
02/04/202422:05GlobeNewswire Inc.Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
04/03/202414:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsNASDAQ:PCVXVaxcyte Inc
27/02/202422:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PCVXVaxcyte Inc
27/02/202422:01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
15/02/202422:05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:PCVXVaxcyte Inc
03/02/202400:39GlobeNewswire Inc.Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
01/02/202422:05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:PCVXVaxcyte Inc
31/01/202423:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCVXVaxcyte Inc
31/01/202405:37GlobeNewswire Inc.Vaxcyte Announces Pricing of $750 Million Public OfferingNASDAQ:PCVXVaxcyte Inc
30/01/202422:01GlobeNewswire Inc.Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:PCVXVaxcyte Inc
29/01/202414:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
16/01/202422:01GlobeNewswire Inc.Vaxcyte Appoints Whitney Jones as Chief People OfficerNASDAQ:PCVXVaxcyte Inc
04/01/202422:01GlobeNewswire Inc.Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseNASDAQ:PCVXVaxcyte Inc
05/12/202300:35GlobeNewswire Inc.VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateNASDAQ:PCVXVaxcyte Inc
29/11/202322:46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
28/11/202314:30GlobeNewswire Inc.Vaxcyte Appoints Jacks Lee to Board of DirectorsNASDAQ:PCVXVaxcyte Inc
27/11/202322:00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:PCVXVaxcyte Inc
09/11/202314:30GlobeNewswire Inc.Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
06/11/202322:03GlobeNewswire Inc.Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
31/10/202321:05GlobeNewswire Inc.Vaxcyte to Present at Upcoming Investor ConferencesNASDAQ:PCVXVaxcyte Inc
19/10/202315:29Dow Jones NewsVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine ApplicationNASDAQ:PCVXVaxcyte Inc
19/10/202314:30GlobeNewswire Inc.Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNASDAQ:PCVXVaxcyte Inc
16/10/202314:00GlobeNewswire Inc.Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)NASDAQ:PCVXVaxcyte Inc
19/09/202322:05GlobeNewswire Inc.Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCVX

La tua Cronologia

LSE
43NP
Lloyds Bk. 24
BIT
P20KS2
NLBNPIT20KS2 20991231 17...
BIT
UC4PPA
Unicredit Bank
NASDAQI
OSV
PHLX Oil Service Sector
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network